-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, while major multinational pharmaceutical companies have announced their financial reports, news of layoffs and other news has also flowed out
.
It is reported that in order to adjust the research and development pipeline, Sanofi plans to lay off 6,000 people
.
Sanofi executives said in a recent quarterly investor conference call that it will continue to implement its layoff plan in 2022, and it is expected to lay off 6,000 jobs globally throughout the year
.
The purpose is to adjust the R&D pipeline and embrace digital reform.
Part of the reasons for the layoffs also include the planned spin-off of EUROAPI (API company)
.
At present, Sanofi has 96,000 employees worldwide.
According to the company's layoff plan, by the end of 2022, the number of employees may be close to 90,000
.
Embracing digital reform is an activity that major pharmaceutical companies are currently carrying out
.
Since 2020, the application of digital technology has accelerated into people's lives and production.
For pharmaceutical companies, the advantages of digital high-efficiency production, unmanned or less human contact are prominent, making up for the traditional production, management and service.
and so on
.
In addition to Sanofi, companies such as Pfizer have said in the future that doctors and other healthcare professionals expect about half of their interactions with pharmaceutical companies to be remote
.
Not long ago, Sanofi also disclosed its performance report
.
On February 4, Sanofi’s 2021 financial report data showed that the net income for the whole year was 37.
761 billion euros (about 43.
006 billion US dollars), a year-on-year increase of 7.
1%
.
The pharmaceutical business revenue totaled 26.
970 billion euros, a year-on-year increase of 7.
6%
.
Among them, Sanofi China market performed strongly, second only to the US market
.
Revenue for the full year was EUR 2.
720 billion, an increase of 7.
9% year-on-year, mainly due to the growth of Dupixent and the recovery of Plavix (clopidogrel) from the impact of volume purchases
.
Judging from the data, Sanofi's business in China will perform well in 2021
.
However, there are still industry analysts who believe that Sanofi’s layoffs may have been impacted by centralized procurement. .
Insight data shows that in 2020, the total size of China's insulin market will be 28.
6 billion yuan
.
Three multinational pharmaceutical companies, Novo Nordisk, Sanofi and Eli Lilly, account for most of the market, of which Sanofi has a 25.
8% market share
.
The results of the sixth batch of special centralized procurement of insulin showed that Sanofi only selected two products, insulin glargine injection and insulin glargine injection, while Sanofi’s market share in insulin glargine has been impacted by local pharmaceutical companies in recent years.
showing a gradual downward trend
.
In addition, judging from the sales of clopidogrel, which Sanofi previously won the bid for, the sales of this product in China will decline by more than 50% in 2020
.
It is expected in the industry that the market of the two newly won bids may also be affected to some extent by clopidogrel in the future
.
Therefore, it is believed that the reduction of personnel by Sanofi this time is to achieve better development of the company
.
Back in 2019, Sanofi planned to reduce operating costs by 2 billion euros by 2022
.
In order to accomplish this goal, Sanofi has actively carried out business streamlining and management restructuring in recent years
.
According to public information, in 2018, Sanofi had a total of about 105,000 employees.
Since then, the company has continued to reduce the number of employees
.
For example, in 2019, Sanofi announced 466 layoffs and gradually withdrawn from research in the field of heart disease; in June 2020, Sanofi announced 1,700 layoffs in Europe; in January 2021, Sanofi announced that it will It will cut 400 jobs in the research and development department in France and thousands of jobs will be cut across Europe
.
While reducing the number of employees, Sanofi is also actively adjusting the company structure
.
According to recent news, He Enting, former general manager of Sanofi Global Business Unit and president of China, and Zhang Heping, general manager of Sanofi Pasteur China, will become the heads of the corresponding departments in Greater China
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is reported that in order to adjust the research and development pipeline, Sanofi plans to lay off 6,000 people
.
Sanofi executives said in a recent quarterly investor conference call that it will continue to implement its layoff plan in 2022, and it is expected to lay off 6,000 jobs globally throughout the year
.
The purpose is to adjust the R&D pipeline and embrace digital reform.
Part of the reasons for the layoffs also include the planned spin-off of EUROAPI (API company)
.
At present, Sanofi has 96,000 employees worldwide.
According to the company's layoff plan, by the end of 2022, the number of employees may be close to 90,000
.
Embracing digital reform is an activity that major pharmaceutical companies are currently carrying out
.
Since 2020, the application of digital technology has accelerated into people's lives and production.
For pharmaceutical companies, the advantages of digital high-efficiency production, unmanned or less human contact are prominent, making up for the traditional production, management and service.
and so on
.
In addition to Sanofi, companies such as Pfizer have said in the future that doctors and other healthcare professionals expect about half of their interactions with pharmaceutical companies to be remote
.
Not long ago, Sanofi also disclosed its performance report
.
On February 4, Sanofi’s 2021 financial report data showed that the net income for the whole year was 37.
761 billion euros (about 43.
006 billion US dollars), a year-on-year increase of 7.
1%
.
The pharmaceutical business revenue totaled 26.
970 billion euros, a year-on-year increase of 7.
6%
.
Among them, Sanofi China market performed strongly, second only to the US market
.
Revenue for the full year was EUR 2.
720 billion, an increase of 7.
9% year-on-year, mainly due to the growth of Dupixent and the recovery of Plavix (clopidogrel) from the impact of volume purchases
.
Judging from the data, Sanofi's business in China will perform well in 2021
.
However, there are still industry analysts who believe that Sanofi’s layoffs may have been impacted by centralized procurement. .
Insight data shows that in 2020, the total size of China's insulin market will be 28.
6 billion yuan
.
Three multinational pharmaceutical companies, Novo Nordisk, Sanofi and Eli Lilly, account for most of the market, of which Sanofi has a 25.
8% market share
.
The results of the sixth batch of special centralized procurement of insulin showed that Sanofi only selected two products, insulin glargine injection and insulin glargine injection, while Sanofi’s market share in insulin glargine has been impacted by local pharmaceutical companies in recent years.
showing a gradual downward trend
.
In addition, judging from the sales of clopidogrel, which Sanofi previously won the bid for, the sales of this product in China will decline by more than 50% in 2020
.
It is expected in the industry that the market of the two newly won bids may also be affected to some extent by clopidogrel in the future
.
Therefore, it is believed that the reduction of personnel by Sanofi this time is to achieve better development of the company
.
Back in 2019, Sanofi planned to reduce operating costs by 2 billion euros by 2022
.
In order to accomplish this goal, Sanofi has actively carried out business streamlining and management restructuring in recent years
.
According to public information, in 2018, Sanofi had a total of about 105,000 employees.
Since then, the company has continued to reduce the number of employees
.
For example, in 2019, Sanofi announced 466 layoffs and gradually withdrawn from research in the field of heart disease; in June 2020, Sanofi announced 1,700 layoffs in Europe; in January 2021, Sanofi announced that it will It will cut 400 jobs in the research and development department in France and thousands of jobs will be cut across Europe
.
While reducing the number of employees, Sanofi is also actively adjusting the company structure
.
According to recent news, He Enting, former general manager of Sanofi Global Business Unit and president of China, and Zhang Heping, general manager of Sanofi Pasteur China, will become the heads of the corresponding departments in Greater China
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
